Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
720
Trial Sponsor
Clinical Trial Start Date
October 4, 2019
0Primary Completion Date
October 23, 2023
0Study Completion Date
October 23, 2023
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
IL-20
Fludarabine0
Rituximab0
Obinutuzumab0
FT5160
Cyclophosphamide0
Bendamustine0
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma0
Last Updated
October 26, 2023
0Allocation Type
Non-Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Study summary
This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
